Biocytogen Enters into RenMab(TM)/RenLite(TM) Licensing Agreement with Xencor

Xencor to use RenLite(TM) Fully Human Antibody Mouse Platform to discover novel antibody drugs

WAKEFIELD, Mass. and BEIJING, Dec. 7, 2020 /PRNewswire/ -- Beijing Biocytogen Co., Ltd., Biocytogen Boston Corp (collectively as "Biocytogen") announced today that they have reached an agreement with Xencor, Inc., for the licensing of Biocytogen's fully human antibody RenMab(TM)/RenLite(TM) Mouse platform to enhance Xencor's monoclonal antibody drug discovery research. []

The leading platform for fully human antibody generation

The RenMab(TM) Mouse was developed using Biocytogen's unique chromosome engineering technique. In this model, the Ig genes that encode for antibody variable domains of heavy and light chains are fully replaced by human corresponding Ig genes . The RenLite(TM) Mouse is a genetically engineered model with complete humanization in the variable region of the heavy chains, while maintaining a single human light chain. These models can be used to fast generate and screen fully human antibody hits and thus identify therapeutic candidates with high affinities, specificities, and diversities more efficiently than by using other available technology platforms.

Xencor is a leading clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases. Xencor and Biocytogen have collaborated on preclinical pharmacology studies, and Xencor moved forward with the new licensing agreement after Biocytogen released RenLite((TM))'s robust validation data [].

"We are excited to begin this collaboration," said Dr. John Desjarlais, Xencor's CSO. "We anticipate the RenMab and RenLite platforms will extend our bispecific antibody discovery and look forward to working with the team at Biocytogen."

The agreement, reached on October 27, includes licenses for the RenMab(TM) and RenLite(TM) mouse platforms and Biocytogen's ongoing support of Xencor's drug development efforts to help meet the increasing global demand for effective biologic therapies.

"We are delighted that Xencor has selected the Biocytogen RenMab(TM)/RenLite(TM) mice for their development of novel fully human antibody candidates," said YueLei Shen, Founder and CEO of Biocytogen. "We are highly confident that the combination of our fully-humanized mouse model and Xencor's proven expertise in drug discovery and development will provide the ideal collaboration for the Xencor's discovery of clinically-relevant antibodies."

The RenMab(TM) and RenLite(TM) antibody platforms are available for licensing to pharmaceutical and biotechnology partners seeking to streamline their antibody discovery workflow. For more information on RenMab(TM) and RenLite(TM), visit [].

About Biocytogen

Based on the fully human antibody RenMab(TM), RenLite(TM), and RenNano(TM) Mice, Biocytogen has integrated its platforms in single-cell antibody discovery, gene editing, large-scale animal model supply, and screening to form a new approach to streamline the entire drug development process. Biocytogen collaborates with global partners to accelerate new drug discovery and development. For more information, please visit [].

Forward-Looking Statement

The information in this press release may include "forward-looking statements," which involve unknown risk or uncertainties. These forward-looking statements usually contain words such as "anticipate", "plan", "expect", "project", "future", "estimate", "predict", "potential", "seek," "forecast", "intend," "believe," "may", "will", "should", "could", and other similar words forecasting future outcomes. Although forward-looking statements contained in this material are based upon Biocytogen's best judgement under the current circumstances, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ from those anticipated in such statements. The Company undertakes no obligation to update forward-looking statements if circumstances or outcomes should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

For more information Qingcong Lin, CEO Biocytogen Boston Corp 781-587-3555

Logo - []

Web site:

PR Newswire

Dit persbericht is via ANP Pers Support naar internationale (vak en online) media gestuurd. Heb je nieuws voor buitenlandse journalisten? Bekijk dan onze mogelijkheden of neem contact met ons op.

Verstuur nu éénmalig een persbericht

Verstuur persberichten en beeldmateriaal naar redacties in binnen- en buitenland. Via het ANP-net, het internationale medianetwerk van PR Newswire of met een perslijst op maat.

Direct persbericht versturen
070 - 41 41 234